You are here

Meeting Highlights

FDA Advisory Committee Meeting on Prasugrel for Acute Coronary Syndromes

Walter Alexander
PDF version: 
If approved by the FDA, the platelet inhibitor prasugrel will be a first-in-its-class competitor of clopidogrel (Plavix). The new drug is designed to reduce the risk of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular disease, but bleeding and the risk of neoplasms can result.